13 results
8-K
EX-99.1
GLTO
Galecto Inc
23 Oct 23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
9:00am
of the antibodies to their respective targets. GB1211 is designed to counter these effects.
About the GALLANT-1 trial
The Phase 1b/2a trial of GB1211
8-K
EX-99.1
GLTO
Galecto Inc
5 Jan 22
Regulation FD Disclosure
4:02pm
at high concentrations GB0139 targets macrophages – the cells driving the fibrosis mechanism Unique and pluripotent MoA GB0139 inhibits fibrosis
10-K
2020 FY
GLTO
Galecto Inc
29 Mar 21
Annual report
6:03am
of treating most of the forms of lung fibrosis. GB0139 targets galectin-3, one of the key regulators of fibrosis. The overexpression of galectin-3 … potential drugs in clinical development.
We believe that our founders’ and management’s experience provides unique insights into the targets
424B4
w2q q1jtsy
30 Oct 20
Prospectus supplement with pricing info
4:31pm
S-1/A
EX-10.3
1w17i y052sh
22 Oct 20
IPO registration (amended)
6:13am
S-1/A
iwx oqccqgb1fheuch
22 Oct 20
IPO registration (amended)
6:13am
S-1
EX-10.8
l3t2p9pg def9
7 Oct 20
IPO registration
5:01pm
S-1
EX-10.7
ajt8iiil u1w23v5
7 Oct 20
IPO registration
5:01pm
S-1
3pw fjpbotrgdw
7 Oct 20
IPO registration
5:01pm
S-1
EX-10.10
3ofbb
7 Oct 20
IPO registration
5:01pm
DRS
7x7yfq47pt l70jt34
2 Sep 20
Draft registration statement
12:00am
- Prev
- 1
- Next